Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061293 · ClinicalTrials.gov registry record · Phase 2
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT02061293 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 95 participants.
The verdict
NCT02061293, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
Several lines of evidence suggest that classic hallucinogens such as psilocybin can facilitate behavior change in addictions such as alcohol dependence. The proposed investigation is a multi-site, double-blind active-controlled trial (n = 180, 90 per group) contrasting the acute and persisting effects of psilocybin to those of diphenhydramine in the context of outpatient alcoholism treatment.
Interventions
- DRUG Psilocybin
- DRUG Diphenhydramine
- BEHAVIORAL Motivational Enhancement and Taking Action (META)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-06 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02061293
The ClinicalTrials.gov registry entry for NCT02061293 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Psilocybin is the first listed.
NCT02061293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02061293 about?
NCT02061293 is a clinical study titled "A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence". Several lines of evidence suggest that classic hallucinogens such as psilocybin can facilitate behavior change in addictions such as alcohol dependence. The proposed investigation is a multi-site, double-blind active-controlled trial (n = 180, 90 per group) contrasting the acute and persisting effec...
What is the current status of trial NCT02061293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2014-06. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT02061293?
The interventions under investigation include: Psilocybin (DRUG), Diphenhydramine (DRUG), Motivational Enhancement and Taking Action (META) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02061293?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.